BLUEJET Blue Jet Healthcare Q4 FY26 results (Jan–Mar 2026) and concall
Blue Jet Healthcare reported a mixed Q4 and FY26, with strong growth in the contrast media segment partially offsetting a significant decline in the PI/API business due to customer destocking. The company initiated its large-scale Vizag greenfield expansion and an R&D center in Hyderabad, laying foundations for future growth. Despite a relatively flat FY26 revenue and muted EBITDA, management expressed confidence in FY27 with improved visibility and new product launches, while maintaining a debt-free balance sheet.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 30.9%, net profit down 41.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 208 | 318 | 340 | 355 | 165 −21% | 192 −40% | 235 −31% |
| EBITDA | 69 | 124 | 140 | 121 | 55 −20% | 47 −62% | 71 −49% |
| Net profit | 58 | 99 | 110 | 91 | 52 −10% | 40 −60% | 64 −42% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
